Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belcesiran phase 2 trial in alpha-1 antitrypsin deficiency-associated liver disease
NL-OMON55922Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2022
- Modality
- Gene Therapies, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of belcesiran in alpha-1 antitrypsin deficiency (AATD) (8 cohorts), sponsored by Novo Nordisk. Started Sep 2022; status: completed.
02
Drugs
belcesiran
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NL-OMON55922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55922.